Publications by authors named "Scott Gettinger"

Claim this Profile
A
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status.
Lyudmila Bazhenova, J G Hodgson, D Ross Camidge, Corey J Langer, Rudolf M Huber, Scott Gettinger

Clin Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.
Alessio Cortellini, Edoardo Garbo, Giulia La Cava, Fabrizio Citarella, Valentina Santo, Scott Gettinger

Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025.
Gregory J Riely, Douglas E Wood, Dara L Aisner, Billy W Loo, Andrea L Axtell, Scott Gettinger

J Natl Compr Canc Netw· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.
Alessio Cortellini, Valentina Santo, Leonardo Brunetti, Edoardo Garbo, David J Pinato, Scott Gettinger

J Immunother Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Gregory J Riely, Douglas E Wood, Billy W Loo, Dara L Aisner, Wallace Akerley, Scott Gettinger

J Natl Compr Canc Netw· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.
Alessio Cortellini, Leonardo Brunetti, Giuseppina Rita Di Fazio, Edoardo Garbo, David J Pinato, Scott Gettinger

J Immunother Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors.
Adam J Schoenfeld, Sylvia M Lee, Bernard Doger de Spéville, Scott N Gettinger, Simon Häfliger

Cancer Discov· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Trial of Afatinib in Patients With -Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A.
Scott N Gettinger, Zihe Song, Karen L Reckamp, Jeffrey A Moscow, Robert J Gray

JCO Precis Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology.
Gregory J Riely, Douglas E Wood, David S Ettinger, Dara L Aisner, Wallace Akerley, Scott Gettinger

J Natl Compr Canc Netw· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial.
Edwin Roger Parra, Jiexin Zhang, Dzifa Yawa Duose, Edgar Gonzalez-Kozlova, Mary W Redman, Scott Gettinger

Clin Cancer Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.
Bomiao Hu, Marc Wiesehöfer, Fernando J de Miguel, Zongzhi Liu, Lok-Hei Chan, Scott Gettinger

Cancer Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Mesothelioma: Pleural, Version 1.2024.
James Stevenson, David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Scott Gettinger

J Natl Compr Canc Netw· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer.
Paul Stockhammer, Michael Grant, Anna Wurtz, Giorgia Foggetti, Francisco Expósito, Scott Gettinger

J Thorac Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
David S Ettinger, Douglas E Wood, James Stevenson, Dara L Aisner, Wallace Akerley, Scott Gettinger

J Natl Compr Canc Netw· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autologous humanized PDX modeling for immuno-oncology recapitulates features of the human tumor microenvironment.
Michael Chiorazzi, Jan Martinek, Bradley Krasnick, Yunjiang Zheng, Keenan J Robbins, Scott Gettinger

J Immunother Cancer· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Treatment of Driver-Negative Non-Small Cell Lung Cancer.
So Yeon Kim, Scott Gettinger

Hematol Oncol Clin North Am· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I.
Joseph M Unger, Lu Qian, Mary W Redman, Susan S Tavernier, Lori Minasian, Scott N Gettinger

J Natl Cancer Inst· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Scott Gettinger

J Natl Compr Canc Netw· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG).
Shing M Lee, Weijia Fan, Aijin Wang, Riha Vaidya, Mary W Redman, Scott N Gettinger

JCO Clin Cancer Inform· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory + NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials.
Scott N Gettinger, Rudolf M Huber, Dong-Wan Kim, Lyudmila Bazhenova, Karin Holmskov Hansen

JTO Clin Res Rep· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microwave Ablation versus Stereotactic Body Radiotherapy for Stage I Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis.
Xiao Wu, Johannes Uhlig, Justin D Blasberg, Scott N Gettinger, Robert D Suh

J Vasc Interv Radiol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced -Positive NSCLC.
Dong-Wan Kim, Shirish Gadgeel, Scott N Gettinger, Gregory J Riely, Geoffrey R Oxnard

JTO Clin Res Rep· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Scott Gettinger

J Natl Compr Canc Netw· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer-Reply.
Scott Gettinger, Mary W Redman, Roy S Herbst

JAMA Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James C H Yang, Ji-Youn Han, Scott N Gettinger

J Thorac Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis